CCCarmen Capito

Carmen Capito

*This is an algorithmically generated author record based on publicly available information.

Carmen Capito has a total of 116 co-authors. Here are the top co-authors by number of shared publications:

  • Christophe Chardot

    Service Chirurgie pédiatrique, Transplantation, AP‐HP, Hôpital Necker Enfants Malades Paris France

    5 shared publications
  • Florence Lacaille

    Service Gastroentérologie‐Nutrition pédiatriques et Unité d'Hépatologie Transplantation Pédiatrique, AP‐HP, Hôpital Necker Enfants Malades Paris France

    4 shared publications
  • Samira Sissaoui

    Paediatric hepatology, Hôpital Necker enfants maladies, Paris, France

    3 shared publications
  • Stefania Querciagrossa

    Paediatric anaesthesiology, Hôpital Necker enfants maladies, Paris, France

    3 shared publications
  • Christophe Chardot

    Pediatric Surgery, Hôpital Necker - Enfants Malades, Paris, France

    2 shared publications
  • Fabrizio Vatta

    Department of Pediatric Surgery and Urology, Hôpital Necker-Enfants Malades, Paris, France

    2 shared publications

Latest Publications

  • Focal congenital hyperinsulinism: spontaneous glycemic improvement before surgery

    by Jean-Baptiste Arnoux, Claire Mayer, Imen Jhaouat, Cécile Saint-Martin, Claire-Marine Bérat, Lucile Altenburger, Anaïs Brassier, Juliette Bouchereau, Stefania Querciagrossa, Olivier Bustarret, et al.

    Context: Congenital hyperinsulinism (CHI) is the most common genetic cause of hypoglycemia in infants. Severe CHI may result from a focal pancreatic lesion (FoCHI), which can be surgically removed, although postoperative complications may occur, particularly after pancreatic head resections. Objective: To describe the spontaneous glycemic evolution of FoCHI before surgery and to assess the potential role of conservative management. Methods: We retrospectively reviewed medical records of patients with FoCHI managed at a single referral center. Congenital hyperinsulinism severity was classified according to the need for continuous gastric tube feeding (TF) to maintain glycemic control prior to surgery, defining a TF group and a no–tube feeding (NTF) group. Results: Thirty-nine patients were included: 12 (30.8%) in the NTF group and 27 (69.2%) in the TF group. Patients in the NTF group were diagnosed later (P = .022), had less severe initial hypoglycemia (P = .003), and 4/12 did not undergo surgery and were cured of hypoglycemia before 6 years of age. We developed an exploratory predictive score for early disease evolution, showing a specificity of 97%. Surgery was curative in most patients (96.3% in the TF group, 100% in the NTF group). Long-term complications were uncommon (8.6% vs 0%) and consisted exclusively of exocrine pancreatic insufficiency, occurring only after pancreatic head surgery (15.8%). Conclusion: Approximately 30% of infants with FoCHI demonstrated rapid early improvement. While surgery remains the standard curative treatment, a conservative approach may be considered in selected infants with pancreatic head lesions who show early favorable glycemic evolution, potentially after surgical exploration to assess postoperative risk.

  • Piperacillin Population Pharmacokinetics in Plasma and Peritoneal Fluid and Dosing Optimization in Children Undergoing Liver Transplant: An Optimome Study

    by Noémie de Cacqueray, Mehdi Oualha, Frantz Foissac, Leo Froelicher Bournaud, Gabrielle Lui, Emmanuelle Bille, Christophe Chardot, Carmen Capito, Florence Lacaille, Philippine Widmer, et al.

    Piperacillin–tazobactam is frequently used in children undergoing liver transplantation (LT), yet its pharmacokinetics (PK) in this population remains poorly characterized. We aimed to develop a population pharmacokinetic model for piperacillin in plasma and peritoneal fluid in children undergoing LT and to optimize dosing regimen for this population. We conducted a retrospective, single‐center, observational study including all children receiving piperacillin–tazobactam as prophylaxis for LT and had at least one piperacillin concentration in both plasma and peritoneal fluid. PK analysis was conducted using nonlinear mixed effect modeling (Monolix) and was part of Optimome study. We included 31 patients with a median (range) age of 4 years (4 months–17 years). A total of 172 plasma and 146 peritoneal fluid samples were analyzed. Plasma concentrations were best fitted by a one‐compartment model with first‐order elimination. A virtual effect site compartment was added to adequately describe piperacillin concentrations in plasma and peritoneal fluid. Allometrically scaled body weight (pre‐transplant and current values) and glomerular filtration rate (eGFR) were identified as significant covariates. Median (range) peritoneal/plasma AUC 0–24h ratio was 72 (45–94) %. Simulations showed that optimal dosing regimens ranged from 300 mg/kg/day (q6h over 3 hours) to 400 mg/kg/day as a continuous infusion, depending on the PK target (i.e., f T >1 × MIC or f T >4 × MIC ) and patient eGFR. In children undergoing LT, body weight and renal function explained some of the between subject variability for piperacillin PK. Higher dosing regimen combined with therapeutic drug monitoring is necessary to optimize exposure in plasma and at surgical site.

  • Open Access

    Molecular evolution of mosaic chromosome 18 copy-number alterations from gametes to hepatoblastoma

    by Elise Cendres, Marianna Cornet, Zoé Gautier, Aurore Pire, Noémie Urvoy, Guillaume Morcrette, Fatoumata Simaga, Anne Guimier, Christophe Chardot, Carmen Capito, et al.

  • Développement du pancréas humain embryonnaire ex vivo / in vivo : La greffe musculaire : un nouveau modèle d'étude longitudinale et dynamique

    by Carmen Capito

    Au-delà de l’intérêt cognitif de la démarche, la compréhension des mécanismes qui régissent le développement pancréatique humain reste la clé pour décrypter les acteurs physiopathologiques des maladies du pancréas et pour développer des approches thérapeutiques innovantes. En outre, alors que la cellule bêta de rongeurs et la cellule bêta humaine partagent un grand nombre de similitudes, certaines données indiquent également des différences marquées entre les espèces. L'absence de systèmes expérimentaux robustes , à partir de matériel humain, n'a pas permis un examen détaillé du développement pancréatique humain jusqu’à présent. Dans le laboratoire, il a été précédemment validé un modèle de xénogreffe de pancréas immature humain sous la capsule rénale de souris immuno-incompétentes SCID. Il a été démontré que celui-ci permettait de récapituler l’ensemble des étapes du développement endocrine humain. Néanmoins le site de greffe limitait les possibilités de modifier ce développement, notamment par infection virale. Dans ce travail, nous avons développé et validé un nouveau site de greffe dans le muscle squelettique, plus simple et plus superficiel. En outre, nous démontrons qu’il est possible de créer un pancréas humain partiellement transgénique in vivo en réalisant du transfert de gènes médié par des lentivirus, après injection directe de la solution virale dans le greffon. Ce modèle de greffe dans le muscle est une nouvelle approche permettant d’envisager des études longitudinales, dans lesquelles il serait possible d’étudier la régulation de certains gènes ou le devenir de certaines lignées marquées par des gènes rapporteurs apportés par le virus à différents stades de développement.

  • Is a history of umbilical vein catheterization a contraindication to Meso-Rex bypass for extrahepatic portal vein obstruction in children?

    by Rani Kassir, Marianna Gortan, Cécile Lozach, Klervie Loiselet, Philippe Drabent, Federica di Corte, Stefania Querciagrossa, Olivier Bustarret, Myriam Jugie, Ugo Cucinotta, et al.

  • Open Access

    Robotic-assisted laparoscopic Ladd's procedure placing the ports along the Pfannenstiel line: A case report

    by Fabrizio Vatta, Ulysse Laplanche, Véronique Rousseau, Carmen Capito, Thomas Blanc

  • Open Access

    Robot-Assisted Surgery in Pediatric Patients: Results of a French Multicenter Study on 1401 Patients

    by Quentin Ballouhey, Ciro Esposito, Kiarash Taghavi, Hubert Lardy, Nicolas Berte, Olivier Abbo, Marc David Leclair, Sarah Garnier, Matthieu Peycelon, Géraldine Hery, et al.


  • Split Liver Transplantation

    by Lucas Rabaux, Christophe Chardot, Carmen Capito

  • Adverse Events and Morbidity in a Multidisciplinary Pediatric Robotic Surgery Program. A prospective, Observational Study

    by Nicolas Vinit, Fabrizio Vatta, Aline Broch, Mary Hidalgo, Jules Kohaut, Stefania Querciagrossa, Vincent Couloigner, Naziha Khen-Dunlop, Nathalie Botto, Carmen Capito, et al.

    Objective: To report one-year morbidity of robotic-assisted laparoscopic surgery (RALS) in a dedicated, multidisciplinary, pediatric robotic surgery program. Summary Background Data. RALS in pediatric surgery is expanding, but data on morbidity in children is limited. Methods: All children who underwent RALS (Da Vinci Xi, Intuitive Surgical, USA) were prospectively included (October 2016 to May 2020; follow-up ≥1 year). Analyzed data: patient characteristics, surgical indication/procedure, intraoperative adverse events (ClassIntra classification), blood transfusion, hospital stay, postoperative complications (Clavien-Dindo). Results: Three hundred consecutive surgeries were included: urology/gynecology (n=105), digestive surgery (n=83), oncology (n=66), ENT surgery (n=28), thoracic surgery (n=18). Median age and weight at surgery were 9.5 [interquartile range (IQR)=8.8] years and 31 [IQR=29.3] kg, respectively. Over one year, 65 (22%) children presented with ≥1 complication, with Clavien-Dindo ≥III in 14/300 (5%) children at ≤30 days, 7/300 (2%) at 30-90 days, and 12/300 (4%) at >90 days. Perioperative transfusion was necessary in 15 (5%) children, mostly oncological (n=8). Eight (3%) robotic malfunctions were noted, one leading to conversion (laparotomy). Overall conversion rate was 4%. ASA ≥3, weight ≤15 kg, and surgical oncology did not significantly increase the conversion rate, complications, or intraoperative adverse events (ClassIntra ≥2). ASA score was significantly higher in children with complications (Clavien-Dindo ≥III) than without (p=0.01). Median hospital stay was 2 [IQR=3] days. Three children died after a median follow-up of 20 [IQR=16] months. Conclusions: RALS is safe, even in the most vulnerable children with a wide scope of indications, age, and weight. Robot-specific complications or malfunctions are scarce.


  • Antithrombin supplementation for prevention of vascular thrombosis after pediatric liver transplantation

    by Maria Hukkinen, Michela Wong, Zeynep Demir, Radhia Hadj Salem, Dominique Debray, Sylvain Renolleau, Samira Sissaoui, Florence Lacaille, Muriel Girard, Mehdi Oualha, et al.